TENAX THERAPEUTICS, INC.
جودة البيانات: 100%
TENX
NASDAQ
Manufacturing
Chemicals
KWD 14.02
▼
KWD 0.76
(-5.14%)
6 months return
—
Momentum
Neutral
ROE
-52.72%
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-52.72%
أعلى من متوسط القطاع (-54.68%)
ROIC-44.65%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio15.58
Interest CoverageN/A
التقييم
PE (TTM|NTM)
-4.96 | -9.87
أقل من متوسط القطاع (-1.50)
P/B Ratio2.71
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -35.80 M
Price History
الاتجاهات المالية
السعر المستهدف للمحللين
7 محللين
Buy
+110.9%
upside to target
الحالي
KWD 14.02
Consensus Target
KWD 29.57
KWD 20.00
أدنى
KWD 35.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-9.87
ربحية السهم المستقبلية
-KWD 1.46
الإيرادات المقدّرة
0.0
مفاجآت الأرباح
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -KWD 0.40
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -KWD 0.28 | -KWD 0.27 | -KWD 0.40 | -KWD 0.38 | — | — |
| Estimate | -KWD 0.41 | -KWD 0.45 | -KWD 1.12 | -KWD 0.42 | -KWD 0.40 | -KWD 0.41 |
| المفاجأة | +31.71% | +39.66% | +64.41% | +8.43% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -52.72% · Net Margin: N/A
Profitability
ROE: -52.72% · Net Margin: N/A| Revenue (TTM) | 0.0 | Net Income (TTM) | -52.60 M |
| ROE | -52.72% | ROA | -50.41% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -35.80 M |
| ROIC | -44.65% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 15.58
Safety
D/E: N/A · Current: 15.58| Debt / Equity | N/A | Current Ratio | 15.58 |
| Interest Coverage | N/A | Asset Turnover | 0.00 |
| Working Capital | 96.21 M | Tangible Book Value | 96.21 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -4.96 · EV/EBITDA: N/A
Valuation
P/E: -4.96 · EV/EBITDA: N/A| P/E Ratio | -4.96 | Forward P/E | -9.87 |
| P/B Ratio | 2.71 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -13.73% | ||
| Market Cap | 260.72 M | Enterprise Value | 161.32 M |
Per Share
EPS: -1.34 · FCF/Share: -2.08
Per Share
EPS: -1.34 · FCF/Share: -2.08| EPS (Diluted TTM) | -1.34 | Revenue / Share | 0.00 |
| FCF / Share | -2.08 | OCF / Share | -2.08 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 68.06% · CapEx/Rev: N/A
Efficiency
FCF Conv: 68.06% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 68.06% |
| SBC-Adj. FCF | -50.17 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | — | — | — |
| Net Income | -52.60 M | -17.60 M | 7.71 M | -11.05 M | -32.47 M |
| EPS (Diluted) | -1.34 | -1.15 | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -56.39 M | -19.49 M | 8.23 M | -11.05 M | 32.73 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 32.67 M | 12.71 M | 3.23 M | 5.38 M | 25.15 M |
| SG&A Expenses | — | — | — | — | 7.58 M |
| D&A | — | 0.0 | 7,570.0 | 5,143.0 | 4,116.0 |
| Interest Expense | 0.0 | 23,000.0 | 23,967.0 | 4,443.0 | 949.0 |
| Income Tax | 0.0 | 0.0 | — | 0.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 104.23 M | 96.69 M | 11.68 M | 3.40 M | 5.99 M |
| Total Liabilities | 7.16 M | 4.69 M | 3.59 M | 1.91 M | 1.75 M |
| Shareholders' Equity | 97.07 M | 91.99 M | 8.10 M | 1.49 M | 4.24 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 97.60 M | 94.90 M | — | 2.12 M | 5.58 M |
| Current Assets | 104.23 M | 96.69 M | 11.68 M | 3.21 M | 5.69 M |
| Current Liabilities | 7.16 M | 4.69 M | 3.59 M | 1.85 M | 1.56 M |
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير)
مقارنة بشركات مشابهة في Manufacturing
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير) مقارنة بشركات مشابهة في Manufacturing| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -5.0 | -1.5 |
| P/B | 2.7 | 1.6 |
| ROE % | -52.7 | -54.7 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.7 |
| D/E | — | 0.3 |
ETFs Holding This Stock
ETFs Holding This Stock
BRUSX
BRUSX
0.60% weight
{"event":"ticker_viewed","properties":{"ticker":"TENX","listing_kind":"stock","pathname":"/stocks/tenx","exchange":"NASDAQ","country":"US"}}